Want to see HK:6660 full AI Analyst Report?
6660 Stock Chart & Stats
HK$3.49
-HK$0.02(-0.35%)
At close: 4:00 PM EST
HK$3.49
-HK$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeHK$1.20 - HK$4.48
Previous CloseN/A
Volume905.00K
Average Volume (3M)384.19K
Market Cap
HK$2.12B
Enterprise ValueHK$4.06K
Total Cash (Recent Filing)HK$193.15M
Total Debt (Recent Filing)HK$1.77B
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding507,673,700
10 Day Avg. Volume98,940
30 Day Avg. Volume384,186
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.28
Price to Sales (P/S)3.06
P/FCF Ratio-20.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$3.68B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained gross margins in the 62%–74% range suggest that vaccine and biologics products can retain meaningful value after direct production costs, providing a foundation for future operating improvement if expenses are controlled.
Positive Operating Cash FlowPositive operating cash flow indicates that core activities generated cash before investment spending in the latest periods. This provides a more durable funding base for operations, although continued investment currently prevents positive free cash flow.
Integrated Vaccine Business ModelAn end-to-end model spanning vaccine development, manufacturing, and commercialization can improve control over product execution and market access. This structure may support longer-term scaling if pipeline programs achieve approval and adoption.
Bears Say
Revenue DeclineDeclining revenue signals weaker commercial traction or volatility in product demand and procurement. Without a sustained recovery, lower scale can limit operating leverage, constrain reinvestment, and make it harder to absorb the company’s fixed costs.
Persistent LossesLarge ongoing losses and negative returns on equity indicate that the current business has not converted its product and development activities into shareholder value. Persistent losses could require additional funding and weaken financial flexibility over time.
Negative Free Cash FlowContinued free-cash-flow consumption means operating cash generation does not cover investment spending. If this persists, the company may depend on external financing, increasing funding risk and limiting resources available for pipeline development.
AIM Vaccine Co., Ltd. Class H News
6660 FAQ
What was AIM Vaccine Co., Ltd. Class H’s price range in the past 12 months?
AIM Vaccine Co., Ltd. Class H lowest stock price was HK$1.20 and its highest was HK$4.48 in the past 12 months.
What is AIM Vaccine Co., Ltd. Class H’s market cap?
AIM Vaccine Co., Ltd. Class H’s market cap is HK$2.12B.
When is AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date?
AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 181 days.
How were AIM Vaccine Co., Ltd. Class H’s earnings last quarter?
AIM Vaccine Co., Ltd. Class H released its earnings results on Aug 23, 2026. The company reported -HK$0.117 earnings per share for the quarter.
Is AIM Vaccine Co., Ltd. Class H overvalued?
According to Wall Street analysts AIM Vaccine Co., Ltd. Class H’s price is currently Overvalued.
Does AIM Vaccine Co., Ltd. Class H pay dividends?
AIM Vaccine Co., Ltd. Class H does not currently pay dividends.
What is AIM Vaccine Co., Ltd. Class H’s EPS estimate?
AIM Vaccine Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM Vaccine Co., Ltd. Class H have?
AIM Vaccine Co., Ltd. Class H has 507,673,700 shares outstanding.
What happened to AIM Vaccine Co., Ltd. Class H’s price movement after its last earnings report?
AIM Vaccine Co., Ltd. Class H reported an EPS of -HK$0.117 in its last earnings report. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of AIM Vaccine Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6660
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AIM Vaccine Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AIM Vaccine Co., Ltd. Class H
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Brii Biosciences Limited
―
Pharmaron Beijing Co., Ltd. Class H
―
Clover Biopharmaceuticals Ltd.
―